Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
JAMA. 2011 Jul 20;306(3):294-301. doi: 10.1001/jama.2011.975.
Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) both emerged in the second half of the 20th century, and chronic infection with these agents is among the greatest challenges facing health care in the United States and worldwide. Despite tremendous advances in treatment and management of HIV and HCV, individuals with HIV/HCV coinfection experience a more complicated disease course and treatment. Recognition of the important role that host factors, such as IL28B genotype, have in response to HCV therapy and the emergence of new effective therapies for HCV are actively reshaping the standard of care. These advances may translate into more effective treatment and management of patients with chronic HCV and HIV coinfection in the years ahead.
丙型肝炎病毒 (HCV) 和人类免疫缺陷病毒 (HIV) 均于 20 世纪下半叶出现，而这两种病原体的慢性感染是美国和全球医疗保健面临的最大挑战之一。尽管在 HIV 和 HCV 的治疗和管理方面取得了巨大进展，但 HIV/HCV 合并感染的个体经历更复杂的疾病过程和治疗。宿主因素（如 IL28B 基因型）在 HCV 治疗反应中的重要作用的认识，以及新的有效 HCV 治疗方法的出现，正在积极重塑治疗标准。这些进展可能会在未来几年转化为更有效地治疗和管理慢性 HCV 和 HIV 合并感染的患者。
